BACKGROUND In animals, systemic and intrathecal administration of the alpha2 -adrenergic receptor agonist dexmedetomidine results in robust antinociceptive effects in models of heat pain. In humans, systemically administered dexmedetomidine is approved for sedating patients in the intensive care unit. However, whether systemic administration of dexmedetomidine in humans produces significant ana...

BACKGROUND Intestinal ischemia-reperfusion (I/R) injury is a devastating complication in the perioperative period. Dexmedetomidine is commonly applied in the perioperative period. The authors aimed to determine the effects of different doses of dexmedetomidine (given before or after intestinal ischemia) on intestinal I/R injury and to explore the underlying mechanisms. METHODS Intestinal I/R ...

BACKGROUND Dexmedetomidine is an α(2)-receptor agonist administered by continuous infusion in the intensive care unit (ICU) for sedation of critically ill patients who are undergoing mechanical ventilation following intubation. Relative to ICU patients receiving midazolam (a γ-aminobutyric acid agonist) for sedation, those receiving dexmedetomidine spent less time on ventilation, had fewer epis...

STATEMENT OF FINDINGS: The respiratory effects of dexmedetomidine were retrospectively examined in 33 postsurgical patients involved in a randomised, placebo-controlled trial after extubation in the intensive care unit (ICU). Morphine requirements were reduced by over 50% in patients receiving dexmedetomidine. There were no differences in respiratory rates, oxygen saturations, arterial pH and a...

OBJECTIVE To describe main indications, doses, length of infusion and side effects related to dexmedetomidine infusion. METHODS Observational and retrospective study evaluating dexmedetomidine use in pediatric intensive care unit. RESULTS 77 children received dexmedetomidine infusion longer than 6 hours for mechanical ventilation weaning (32.5%), post- neurosurgery and post-upper airway sur...

objective(s): intestinal ischemia-reperfusion is a major problem, which may lead to multiorgan failure and death. the aim of this study was to evaluate the protective effects of dexmedetomidine on cell proliferation, antioxidant system, cell death, and structural integrity in intestinal injury induced by ischemia-reperfusion in rats. materials and methods: animals were randomized into three gro...

OBJECTIVES/HYPOTHESIS In this study, we compared the effects of propofol and dexmedetomidine on the upper airway collapse pattern and cardiopulmonary parameters of patients with obstructive sleep apnea (OSA) undergoing drug-induced sleep endoscopy (DISE). STUDY DESIGN Prospective, single center, observational study MATERIALS AND METHODS The 50 patients with OSA underwent 30 minutes of DISE ...

AIMS Dexmedetomidine (dexdor®) is approved in the European Union (EU) for sedation of adults in the intensive care unit (ICU). The present observational, retrospective study was requested by the European Medicines Agency to investigate dexmedetomidine use in clinical practice, with a particular focus on off-label use, including the paediatric population. METHODS Study countries and sites were...

BACKGROUND The treatment of cocaine toxicity is an important subject for emergency physicians. We investigated the effects of dexmedetomidine, moxonidine and alpha-methyldopa on acute cocaine toxicity in mice. OBJECTIVES The aim of this study was to evaluate the effects of dexmedetomidine, moxonidine and alpha-methyldopa in a mouse model of acute cocaine toxicity. MATERIALS AND METHODS We p...

Dexmedetomidine is highly selective α2A adrenergic receptor agonist approved for shortterm sedation in an intensive care unit (ICU) setting or in non-intubated patients prior to and/or during surgical and other procedures. Dexmedetomidine is the dextro isomer of medetomidine with eight times greater selectivity for α2-adrenergic receptors than clonidine. This action in the central and periphera...